

# ELRON

## **Translation of Immediate Report Filed by Elron on August 26, 2021 with the Israeli Securities Authority**

Tel-Aviv, August 26, 2021 – Elron Electronic Industries Ltd. (“Elron”) (TASE: ELRN) hereby announces further to Sections 18.4.4.2 and 24 of “Part I – Description of Corporation's Business” in Elron’s annual periodic report for 2020, and following Section 4 of Part I of Elron's quarterly report for the second quarter of 2021, BrainsGate Ltd. (“BrainsGate”) has updated that the FDA has informed BrainsGate that it will bring BrainsGate's marketing approval application to a panel meeting which is expected to take place by the end of the year.

Elron holds approximately 28% of BrainsGate's outstanding share capital as of the filing date, and approximately 25% on a fully diluted basis.

ToHa Tower, 114 Yigal Alon St., 27th floor, Tel Aviv 6744320, Israel

---

Tel: 972-3-6075555 | Fax: 972-3-6075556 | Email: [info@elron.com](mailto:info@elron.com) | [www.elron.com](http://www.elron.com)